Cantor Fitzgerald Weighs in on Ardelyx FY2026 Earnings

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Ardelyx in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings per share of ($0.05) for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.07). The firm had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. The business's revenue for the quarter was up 61.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.11) earnings per share.

Several other brokerages have also recently issued reports on ARDX. BTIG Research initiated coverage on Ardelyx in a research note on Tuesday, March 4th. They issued a "buy" rating and a $14.00 price target for the company. Raymond James lowered Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 target price for the company. in a research report on Friday, May 2nd. Wall Street Zen lowered Ardelyx from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Scotiabank began coverage on Ardelyx in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Finally, Piper Sandler upgraded Ardelyx to a "hold" rating in a research note on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Ardelyx currently has an average rating of "Moderate Buy" and a consensus price target of $10.39.

Ardelyx Stock Performance

NASDAQ ARDX traded down $0.04 during trading on Tuesday, reaching $3.70. 5,648,706 shares of the company's stock were exchanged, compared to its average volume of 4,505,410. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $8.06. The stock has a market capitalization of $885.24 million, a P/E ratio of -23.13 and a beta of 0.59. The business has a 50 day moving average price of $4.23 and a 200-day moving average price of $4.93. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.58 and a quick ratio of 4.31.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARDX. GF Fund Management CO. LTD. purchased a new stake in Ardelyx during the fourth quarter valued at about $25,000. GAMMA Investing LLC raised its position in Ardelyx by 1,342.0% during the first quarter. GAMMA Investing LLC now owns 5,912 shares of the biopharmaceutical company's stock valued at $290,000 after purchasing an additional 5,502 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in Ardelyx during the fourth quarter valued at about $35,000. SBI Securities Co. Ltd. bought a new position in shares of Ardelyx during the fourth quarter valued at about $41,000. Finally, Quarry LP bought a new position in shares of Ardelyx during the fourth quarter valued at about $51,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Ardelyx news, insider Mike Kelliher sold 14,522 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total transaction of $59,249.76. Following the sale, the insider now owns 282,158 shares of the company's stock, valued at $1,151,204.64. The trade was a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Laura A. Williams sold 6,421 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total transaction of $26,197.68. Following the sale, the insider now directly owns 402,583 shares in the company, valued at $1,642,538.64. The trade was a 1.57% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 166,809 shares of company stock valued at $708,914. 4.80% of the stock is owned by company insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.